Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review. Issue 3 (May 2018)

• Record Type: Journal Article
• Authors: Borodovsky, Jacob T.; Levy, Sharon; Fishman, Marc; Marsch, Lisa A.
• Is Part Of: Journal of addiction medicine. Volume 12:Issue 3(2018)
• Publication Date: 2018-05
• Subjects: adolescents -- buprenorphine -- opioid use disorder -- treatment -- young adults; Substance abuse -- Periodicals; Substance abuse -- Treatment -- Periodicals; Substance-Related Disorders -- Periodicals; 616.86005
• DOI: 10.1097/ADM.0000000000000388
• Languages: English
• ISSNs: 1932-0620

Abstract

Abstract : N/A: In the past decade, a new cohort of adolescents and young adults with opioid use disorders (OUD) has emerged. While medications and psychosocial treatments are available, few adolescents and young adults with OUD can access and remain in treatment. Effective, practical, and scalable treatment paradigms for this young population are needed. Buprenorphine is a medication with unique pharmacological and regulatory characteristics that make it a promising component of adolescent and young adult OUD treatment models. Three randomized controlled trials and multiple observational studies have evaluated the use of buprenorphine to treat this population. However, data from these studies have not been consolidated into an up-to-date summary that may be useful to clinicians. The objective of this narrative review is to inform clinical practice by summarizing results of primary and secondary analyses from randomized controlled clinical trials and observational studies that have evaluated the use of buprenorphine to treat adolescents and young adults with OUD. Based on results from these studies, we encourage the conceptualization of OUD among youth as a chronic medical condition requiring a long-term management strategy. This includes treatment with buprenorphine in conjunction with medication-prescribing protocols that do not necessarily require daily clinic attendance for observed medication adherence. However, more study of treatment delivery models, addressing such issues as medication adherence and intensity requirements, is needed to determine practices that optimize outcomes for youth.